for the treatment of overactive bladder (OAB).This is the first time that CTAF has addressed this topic.

For the first time in over 25 years (since the approval of oxybutynin in 1972), better medications are available for the overactive bladder. With the recent approval of tolterodine and oxybutynin ...

Sign In We don’t recognize that sign in. Your username maybe be your email address. Passwords are 6-20 characters with at least one number and letter. We still don’t recognize that sign in.

There is a wide range of variability with how often one should pee, particularly in regard to what’s “normal.” Learn if you ...

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

Oct. 15, 2024 — A team tests the protective effect of a fermented black garlic extract against inflammation and the progression of prostate cancer in a study conducted on human prostate cancer ...

Oct. 9, 2024 — A new study has found some cancers to be slightly more frequent in people with multiple sclerosis (MS) than in people without MS. Types of cancers found to have a small increased ...

Zach began writing for CNET in November, 2021 after writing for a broadcast news station in his hometown, Cincinnati, for five years. You can usually find him reading and drinking coffee or ...

I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness myths. On my spare time I enjoy ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...

Investing in the best Windows laptop ensures top-notch versatility for any type of workload. With exceptional software support, these laptops excel in productivity, creativity, and gaming ...